|Day Low/High||249.25 / 253.97|
|52 Wk Low/High||173.12 / 264.97|
We touched briefly on housing in our first post this morning. There are still some cheap home-building stocks if the housing market continues to improve, which I expect as I believe economic growth will pick up in 2017. I have done well with this se...
Wall Street scores another trifecta of record closes as a rally in the energy and tech sectors drive gains across benchmark indexes.
The biotech probably needs a period of sideways price action before a new rally to the upper end of the trading range gets underway.
If the market is going to overreact to every new missive from Trump, I plan to take advantage.
Investors in biotech stocks appear to be happy with a Trump win and Mizuho's senior biotech analyst says companies in the sector could continue to climb in 2017.
Check out these 15 stocks that boast solid dividend yields and are growing earnings.
But we could see more volatility in the market.
Jim Cramer says there are other reasons not to buy Valeant, other than the criminal investigation.
I continue to believe downside risks far outweigh the risks of a near-term rally.
We may see a respite of the recent pressure for a few days, but it can't be trusted to last.
AMGN is neutral now, but a close below $158 weakens the chart picture.
Both it and Ligand Pharmaceuticals look significantly undervalued relative to their prospects.
Biotech stocks are struggling this year, but investors should not throw in the towel on Amgen, Gilead, bluebird and Bellicum
U.S. stocks climbed and the Dow Jones Industrial Average jumped more than 100 points thanks to gains in the tech and consumer sectors.
The once-mighty biotech has fallen, but entry opportunities will surface.
The shares have some power and legs to get up and through old highs.
The market is basically flat across the board to start the new week, but biotechs are strong overall in early going following news that Pfizer plans to buy Medivation for $14 billion. The sector's movers include some biotechs that I hold. For instan...
RBC Capital analysts say splitting the company into two distinct businesses would free 'trapped value' on drug treatments.
Stocks secure robust gains after the latest labor market snapshot breezes past expectations.
These sectors offer value as the S&P 500 trades at 19x earnings.
The two Big Pharma giants are looking for new ways to drive growth through anti-cancer treatments.
The sector seems to be rebounding after tumbling by more than 40%.
The bifurcation can be seen just by looking at Apple's recent results.
That may be the best way to get through the notorious month of August.